NASDAQ$ARVN
Arvinas Inc. · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
Arvinas reported first quarter 2022 financial results, highlighting a productive quarter as the company prepares to initiate three planned pivotal clinical studies in the second half of 2022 for ARV-471 and bavdegalutamide.
- Presented Phase 1 dose escalation data and interim data from the ongoing Phase 2 ARDENT expansion cohort with bavdegalutamide in metastatic castration-resistant prostate cancer (mCRPC) at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
- Preparing to present data from the VERITAC Phase 2 expansion trial (200 mg and 500 mg) in the second half of 2022.
- Preparing to discuss the potential accelerated approval path with the Food and Drug Administration (FDA) in Q2 2022 for Bavdegalutamide.
- Initiate Phase 2 expansion trial in mCRPC for ARV-766 in the second half of 2022.
Headline financials
Revenue & EPS history
Arvinas · Revenue · Quarterly
$24.2M
Revenue by segment
Arvinas · $30.3M total across 1 segment · Q3 2022
- Collaboration Revenue$30.3M+225.8%100.0%
Forward guidance
Arvinas is focused on advancing its clinical programs and has several milestones expected in 2022.
Tailwinds
- Present data from the VERITAC Phase 2 expansion trial (200 mg and 500 mg) (2H 2022)
- Present safety data from the Phase 1b combination trial with palbociclib (2H 2022)
- Initiate two Phase 3 trials in patients with metastatic breast cancer (as monotherapy and in combination) (2H 2022)
- Initiate a Phase 1b combination trial with cyclin dependent kinase (CDK) inhibitors or other targeted therapies (2H 2022)
- Initiate a pivotal trial in mCRPC for patients with AR T878/H875 tumor mutations (2H 2022)
Headwinds
- The company's net loss increased due to increased research and development expenses, general and administrative expenses, and income tax expense.
- Decrease in cash, cash equivalents, restricted cash and marketable securities was primarily related to cash used in operating activities and unrealized loss on marketable securities.
- The company's future success depends on the successful development and commercialization of its product candidates.
- The company may not be able to obtain marketing approval for its product candidates.
- The company faces risks and uncertainties related to the Pfizer collaboration.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
-2.4%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-0.6%
Avg return
30 days after
30%
9 / 30 earnings
Positive
+11.8%
Q1 2019
Best reaction
-24.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.4% | -10.2% | — | |
| Q4 2025 | +5.2% | +4.7% | -7.4% | |
| Q3 2025 | +0.5% | +17.3% | +34.1% | |
| Q1 2025 | -24.8% | -27.8% | -25.2% | |
| Q4 2024 | -6.8% | -3.5% | -54.9% | |
| Q3 2024 | -3.9% | -2.5% | -2.8% | |
| Q2 2024 | -1.0% | -7.0% | -6.3% | |
| Q1 2024 | +0.3% | -2.5% | -14.1% | |
| Q4 2023 | -5.8% | -3.1% | -15.4% | |
| Q3 2023 | -2.5% | -11.5% | +93.1% | |
| Q2 2023 | +2.1% | +6.8% | +12.8% | |
| Q1 2023 | +4.9% | +3.0% | -1.2% | |
| Q4 2022 | -7.0% | -10.8% | -23.0% | |
| Q3 2022 | -4.0% | +17.9% | -12.5% | |
| Q2 2022 | +3.8% | +4.5% | -19.3% | |
| Q1 2022 | -16.4% | -22.6% | -19.0% | |
| Q4 2021 | -2.6% | -4.4% | -5.4% | |
| Q3 2021 | +4.9% | +1.2% | -18.8% | |
| Q2 2021 | -4.3% | -8.9% | -13.4% | |
| Q1 2021 | -4.0% | -9.1% | -1.7% | |
| Q4 2020 | -1.0% | -8.0% | -15.6% | |
| Q3 2020 | -3.6% | +4.3% | +18.6% | |
| Q2 2020 | -5.0% | -11.1% | -23.0% | |
| Q1 2020 | -0.9% | -6.0% | -17.7% | |
| Q4 2019 | -3.2% | -1.8% | +14.2% | |
| Q3 2019 | +3.3% | +17.6% | +79.4% | |
| Q2 2019 | -4.6% | -0.2% | -1.5% | |
| Q1 2019 | +11.8% | +11.1% | +0.8% | |
| Q4 2018 | -3.0% | -6.9% | +42.9% | |
| Q3 2018 | -0.1% | +7.3% | -13.6% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro